Introduction
Hepatitis C virus (HCV) is one of the first causes of chronic liver disease and it currently affects 130-150 million people worldwide [1] . The infection becomes chronic in 60-85% of patients and leads to the development of hepatic steatosis, fibrosis, cirrhosis and hepatocellular carcinoma [2, 3] . A vaccine against this virus is still not available, while the standard of care was for long a combination of pegylated interferon (pegIFN) and ribavirin, a therapy not specific for HCV and efficient in 50% of treated patients, with many associated side effects [4] . HCV single-stranded, positive-sense, 9.6 kb RNA genome encodes six non-structural proteins (NS2, NS3, NS4A, NS4B, NS5A and NS5B), all essential for the viral replication [5] . In the last decade great progress has been made in the development of safe and highly potent inhibitors of HCV replication targeting the NS3 protease [6, 7] , the NS5B polymerase [8] , the NS4B protein [9] and the NS5A protein [10] . Even if all-oral treatment regimens of chronically infected patients with a combination therapy of either viral NS5B polymerase, NS3 protease or NS5A inhibitors are showing promising results, these treatments are associated with high costs [11, 12] , while resistant viral strains have been reported for each clinically approved direct-acting antiviral [13] [14] [15] [16] [17] . These limitations highlight the need for new therapeutics that will reduce the costs of treatment and avoid the development of resistance.
Despite the abundance of structural and mechanistic information on the HCV NS3 helicase [18] , this enzyme is still underexploited, with very few inhibitors reported so far, none of which taken into clinical development [19] . The protein main function, essential for the viral replication [20, 21] , is the unwinding of double-stranded RNA sequences, formed as an intermediate of the viral nucleic acid synthesis; this process is permitted by ATP hydrolysis [22, 23] .
Due to the essential role of a functional NS3 helicase for HCV replication, this enzyme was chosen as target for the computer-aided identification and synthesis of viral replication inhibitors. The SPECS library of commercially available small molecules [24] was screened in silico on the enzyme known RNA binding cleft, leading to the selection of 21 compounds that were analysed in the HCV replicon assay. A first hit was found to inhibit the viral replication with an EC50 in the sub-micromolar range and a good selectivity index. Its thieno-pyrimidine scaffold was the starting point for the design and synthesis of different series of new analogues, with which the main chemical features were explored. Several new derivatives were found to inhibit the HCV replication with EC50 values in the low or sub-micromolar range.
Results and discussion

Structure-based virtual screening
The HCV NS3 helicase is formed by three domains and occupies the C-terminal portion of the NS3 protein. It presents multiple ligand-binding regions, the main ones being an ATP binding site in the cleft separating domain 1 from domain 2 and a single-stranded nucleic acid binding site at the interface of the three domains [25] . The potential interference with the known nucleic acid binding cleft was evaluated to screen the SPECS library of commercially available compounds [24] . The 3KQH crystal structure, which corresponds to the enzyme high-affinity open conformation bound to a single-stranded DNA substrate [26] , was used for all the analyses performed. The area defined by Glu493, Asn556 and Phe557 was chosen as centre for the creation of a pharmacophoric filter, and the residues essential for the helicase unwinding activity (Thr269, Arg393, Thr411, Glu493 and Trp501) [27] were considered to build the pharmacophore using MOE 2014.10 ( Figure 1) [28]. Among the approximately 450000 structures in the SPECS database, which were analysed with MOE 2014.10 conformational search tool prior to filtration [28] , 3000 hits were found to match the pharmacophoric query. Molecular docking of these compounds in the 3KQH nucleic acid binding cleft was performed using Glide in the standard precision SP mode [29] . The output poses were re-scored with Glide XP [30] , Plants ChemPLP [31] and FlexX [32] scoring functions, and the scoring results were combined using a previously reported consensus scoring procedure [33] . 21 derivatives were finally selected after visual inspection, purchased and tested in the HCV replicon assay (Table S1 ). Compound 1a (Figure 2) showed a promising antiviral effect against HCV replication, with an estimated EC50 <1 µM and a good selectivity index >141 ( Table 1 ). The predicted binding mode found for this structure suggests a good spatial occupation of the target site of the HCV NS3 helicase, with the cyclohexyl portion of the molecule in close proximity to Trp501, the pyrimidine ring filling the space defined by Glu493 and Asn556, and the opportunity of hydrogen-bond formation between the 2'-hydroxyphenyl group and Arg393 lateral chain. Interestingly, 1a shows significant structural similarities with a series of previously published HCV NS3 inhibitors, QU663 ( Figure 3 ) and its derivatives [34] . Furthermore, the predicted binding mode suggested for these structures involves the same sub-pocket of the enzyme nucleic acid binding cleft chosen as target in this study. After the structure of 1a was re-synthesised and its potential to inhibit the HCV replication was confirmed (Table 1) , starting from its scaffold different series of novel thieno-pyrimidine derivatives were designed, synthesised and evaluated.
Chemistry
The structure of 1a is characterized by a central thieno-pyrimidinic nucleus, condensed with a tetrahydrobenzene system at positions 4 and 5 of the thiophene ring, and functionalised with a 2,5-dihydroxyphenyl-ethylidene moiety via a hydrazone linker at position 4 of the pyrimidine ring. Several new derivatives were designed in order to explore the role of the aromatic substituents, the hydrazine linker and the cyclic aliphatic moiety on the thiophene portion.
A first series of differently substituted thieno[2, 3-d] pyrimidin-4-yl)-hydrazones was synthesised according to an optimised five-step synthetic pathway, developed from previously reported procedures (Scheme 1) [35] [36] [37] [38] .
analogue 5g by treatment with 10% Pd/C in toluene for 5 days [39] . As a means to explore the role of the aromatic proton in the pyrimidine ring, its replacement with a methyl group was designed and achieved by condensing aminoester intermediate 5a with acetonitrile instead of formamide. The reaction was performed in a saturated HCl solution in dioxane, under pressure in a sealed tube [40] . The mixture was sonicated in an ultrasonic bath for 4 h in order to solubilise the starting material, then heated at 100 °C for 16 h to obtain pyrimidinone 6h with a methyl group replacing the aromatic proton, after precipitation by the addition of water. With the aim to insert a chlorine substituent at position 6 of the thiophene ring, pyrimidinone 6e was treated with N-chlorosuccinimide in glacial acetic acid for 1.5 h under reflux conditions, giving the desired chlorinated product 6i, which was isolated after precipitation from water in good yield [41] .
Synthetic efforts were also directed to the replacement of the hydrazone linker in the original active scaffold (Scheme 2). In particular, three different chemical functionalities were explored, by the substitution of this bond with a hydrazide, sulfonylhydrazine and amino group, respectively. Scheme 2: Reagents and conditions: (i) 2-Pyridine-sulfonyl chloride, Pyridine, 0 °C, 1 h, r.t., 24h; (ii) Aromatic carboxylic acid, TBTU, DiPEA, THF, r.t., 5 h; (iii) Aryl-amine, NaHCO3, iPrOH, reflux, 96 h.
Compounds 25-36, with a hydrazide linker that confers higher stability in aqueous systems while maintaining the same length of the hydrazone substituent, were obtained through a coupling reaction between hydrazine intermediates 8a-i and aromatic carboxylic acids, using TBTU as coupling agent, stirring the reaction mixture at r.t. in THF in the presence of DIPEA. Compound 37, with a sulfonyl hydrazide linker replacing the original hydrazone group, was obtained by reacting intermediate 8a with 2-pyridinesulfonyl chloride, stirring the two starting materials in pyridine at 0 °C for 1 h and then at r.t. for 24 h.
Finally, a small series of three amino compounds, 38-40, was obtained by aromatic nucleophilic displacement of the chloride leaving group in intermediate 7a with different aromatic amines, refluxing the reaction mixture in iPr-OH for 96 h in the presence of NaHCO3. In this last series of structures, the original three-atom linker is shortened and the substituted phenyl ring is replaced with a condensed bicyclic aromatic moiety. This significant modification on the original structure was designed after a series of conformational analysis studies performed on the structure of 11a, as discussed in paragraph 2.3. All newly
Conformational analysis
In order to understand the role of the 2'-hydroxy group of the hit scaffold, which seems to play a key role for the antiviral activity of the new compounds (Table 1) , the Conformational Search tool in MOE2014.10 was used to analyse the conformational space of 11a in vacuum [28] . An internal hydrogen bond between the 2'-hydroxy group and the nitrogen of the hydrazone linker is predicted to stabilise the lowest energy conformation found (Figure 4 ). In order to freeze this interaction, the replacement of the hydrazone bond with an aromatic amino group was envisaged. This new linker was functionalised with heteroaromatic bicyclic rings, such as 2-benzimidazole (38) and 8-quinoline (39), along with 1-naphthalene (40).
Biological activity
HCV replicon and cytostatic assay
All the newly synthesised thieno-pyrimidines were evaluated for their potential effect against HCV replication in the Huh5-2 replicon system (Table 1) [42] . The HCV protease inhibitor Telaprevir (VX-950) was included as positive control. b EC90 = 90% effective concentration (concentration at which 50% inhibition of virus replication is observed).
c CC50 = 50% cytostatic/cytotoxic concentration (concentration at which 50% adverse effect is observed on the host cell).
d The EC50, EC90 and CC50 values are the mean of at least 2 independent experiments, with standard deviations of ±10% of the value quoted unless otherwise stated (mean value ± standard deviations).
e SI = the ratio of CC50 to EC50.
The presence and position of the two hydroxyl substituents in the structure of 1a seem to play an important role for antiviral activity, since their removal is associated with loss of activity (10a). Of particular importance is the hydroxyl substitution at position 2' of the original scaffold: while 11a shows retained activity in comparison with 1a, 12a, with the sole 3'-hydroxy group, shows complete loss of antiviral potential, thus suggesting a key role for the 2'-OH. The same negative effect is observed for 13a, where the hydroxyl function is moved to the 4'-para position of the phenyl ring. Unsubstituted hydrazine 8a does not show a significant antiviral effect, while removal of the phenylethylidene methyl group (9a) is associated with an increased cytotoxicity in comparison with 1a, with lower values of CC50
and SI. The role of the hydroxyl substituent in the original scaffold was further explored by its replacement with methoxy (14a) and chloro groups (15a): these modifications are associated with activity reduction, thus confirming the importance of the 2'-OH group for the antiviral properties of 1a.
The next step was the exploration of different heteroaromatic rings in the ethylidene portion of the molecule (16-24a): a successful replacement of the original hydroxyl functions is achieved with the introduction of a pyrazine (16a) and 2-benzimidazole (20a), for which the modification seems to be tolerated in terms of EC50. 16a shows the best activity profile found so far in this series, while 17a and 21a, even if showing retained EC50 values, seem to be mainly cytotoxic. Comparison of the biological data found for 16a and 17a with 18a, in which the 3-pyridine substituent is correlated with a dramatic loss of antiviral potential, suggests the same trend previously found for the aromatic hydroxyl groups also in the case of the heteroaromatic nitrogen in the phenylethylidene substituent: the loss of activity found for 18a indicates the same role for a nitrogen in position 2 and a 2'-hydroxyphenyl group.
Furthermore, replacement of 6-membered heteroaromatic rings with 5-membered rings (22a, 23a, 24a),
is associated with loss of activity (23a, 24a) or increased cytotoxicity (22a).
A successful replacement of the original hydrazone group is achieved with the insertion of a hydrazide, as suggested by the biological data found for 25a, 26a, 28a, 29a and 32a, which all show EC50 values equal or below 1 M. 25a and 26a are also associated with good SI values and represent promising candidates for further development, while for 28a, 29a and 32a an increased cytotoxic effect can be observed. Results obtained for 27a, 30a, 31a, 34a, 35a and 36a, which are associated with a dramatic loss of activity, reveal the same trend found in the hydrazone series of compounds for the importance of the hydroxyl group at position 2 (25a and 26a), along with its potential replacement with heteroaromatic moieties with a nitrogen atom at position 2, such as pyrazine (28a) and 2-pyridine (29a), even if these modifications are associated with an increased cytotoxicity in this series of compounds. A second attempt to replace the hydrazone bond with a sulfonylhydrazide (37) led to a dramatic loss of activity. The same consideration can be extended to the replacement of the hydrazone linker with an amine function (38-40), which had been rationally designed as a means to lock the internal hydrogen bond found for 11a.
For all three compounds in this series a significant loss of activity is observed, possibly suggesting that some residual flexibility is important for the biological activity associated with this scaffold.
After having confirmed the antiviral potential associated with the structure originally found and established a preliminary SAR for the phenylethylidene and hydrazone portions, the role of the tetrahydrobenzenic substituent on the thiophene ring was also explored. Six modifications were envisaged for this part of the molecule: an unsubstituted thieno-pyrimidine system, a cyclopentane ring condensed to the thiophene, an oxidised benzene substituent, two methyl groups, and finally two unsymmetrical substitutions, methyl-ethyl and methyl-chloro. Removal of the tetrahydrobenzene substituent seems to be associated with a slight decrease of activity in the hydrazone series (1f, 11f and 18f), along with an increased cytotoxicity found for 11f and 16f. In the hydrazide series this modification is mainly associated with retained activity (28f, 29f) and significantly improved SI values in comparison with the tetrahydrobenzenic counterparts (28a, 29a), even if 26f represents an exception to this trend, with a forty-fold increase in EC50 in comparison with 26a. The replacement of the tetrahydrobenzene substituent with a cyclopentyl ring is mainly associated with retained activity, both in the hydrazone and hydrazide series of analogues. With the exception of 16b, which is mainly associated with a cytotoxic effect, and 1b, which shows a higher EC50 value than 1a and 1c, analogues 11b, 17b, 20b, 25b, 26b, 28b
and 29b are mainly associated with a retained antiviral effect, with 26b showing the most promising profile in this series in terms of both EC50 and SI values. Aromatisation of the cyclohexyl ring is associated with a retained or improved antiviral activity in comparison with the original substituent, for both hydrazone and hydrazide series. With the exception of 16g and 29g, for which an increased cytotoxic effect is observed, retained or improved activity profiles are found for 1g, 11g, 20g, 25g, 26g
and 28g, with EC50 values in the nanomolar range for 11g and 28g, and with a particularly interesting profile found for 11g and 26g, which are associated with good SI values. These data suggest that the rigidity of a tricyclic aromatic system in this part of the molecule is tolerated. A final modification on the thienopyrimidine system was planned to explore the role of the aromatic proton in the pyrimidine ring of 11a, through its replacement with a methyl group. Methylation of the pyrimidine ring is associated with an inconsistent effect among the four compounds tested: while this modification seems to induce activity retention for 16h, 26h and 29h, with EC50 values in the nanomolar range for 16h and 29h, suggesting potential for structural expansion in this part of the molecular scaffold, antiviral activity is completely lost in 11h, which bears a 2'-hydorxyphenyl group in the original hydrazone structure.
HCV NS3 helicase enzymatic assay
A selection among the newly synthesised thieno-pyrimidines was tested for any potential interference with the HCV NS3 helicase activity. In particular, interference with the enzyme unwinding activity was analysed for 41 new analogues (Table S2) , while for 11a, 37, 26b, 11g and 28g additional studies were also performed, and their potential effect of the enzyme ATPase activity and binding to DNA was also assessed. Data for those compounds for which an IC50 can be estimated are summarised in Table 2 .
Primuline [43] and aurintricarboxylic acid [44] were included as positive controls. Despite the fact that 31a, 26b, 1f and 26i show some inhibition of the HCV NS3 helicase unwinding activity at high concentrations, a trend for this effect cannot be identified as it does not seem to be correlated with any specific structural feature. 26b was also found to show inhibition of the enzyme ATPase activity at high concentrations, and this effect can be observed also for 11a, while 37, 11g and 28g were identified as weak inhibitors of DNA binding. Considering all three effect examined, the observed IC50 values are dramatically higher than the range of activities found in the HCV replicon assay
for most of the compounds tested. The lack of correlation between the two sets of data suggests that the antiviral effect of the thieno-pyrimidine structures presented in this study is probably due to a different target, viral or cellular, other than the HCV NS3 helicase. It should also be noted that evaluation of QU663 in similar enzymatic assays did not reveal any significant interference with the helicase ATPase or unwinding activity also for this reference compound [43] .
Conclusions
Starting from a computer-based approach, a substituted thieno-pyrimidine scaffold was identified as promising inhibitor of the HCV replication in the subgenomic replicon assay. Its structure was the starting point for the design and synthesis of different series of new analogues, with which the antiviral potential originally found was confirmed and improved. Several new derivatives were found to be associated with EC50 values in the sub-micromolar or nanomolar range, and different among them are also associated with good SI values. Structure-activity relationships were identified for the biological effect of the scaffold originally found: the presence of a hydrazone linker is essential for antiviral activity, but this group can be successfully replaced with a more stable hydrazide. In order to retain activity, both hydrazone and hydrazide linkers need functionalisation with a six-membered aromatic ring carrying a hydroxyl group at position 2, or a heteroaromatic ring with a nitrogen atom at position 2. The presence of an aliphatic or aromatic substituent in the thienopyrimidine nucleus appears to be beneficial for activity, and suggests expansion potential in this part of the structure. The role of the pyrimidine proton has also been explored: its replacement with a methyl group is mainly associated with activity retention, suggesting also in this case the potential for structural expansion. Preliminary enzymatic evaluations suggest that the antiviral effect associated with the newly prepared compounds is mainly unrelated to the interference with the NS3 helicase activity, and other viral or cellular targets are likely involved.
Understanding the biological target and the mechanism of action of these structures, along with in vitro pre-clinical studies on the most promising new analogues found (11a, 16a, 25a, 26b, 1c, 11c, 1d, 28f, 29f, 11g, 26g), will be the main focus of future studies.
Experimental
Synthetic chemistry methods
All solvents used for chromatography were HPLC grade from Fisher Scientific (UK). 1 H and 13 C NMR spectra were recorded with a Bruker Avance DPX500 spectrometer operating at 500 and 125 MHz, with
Me4Si as internal standard. Mass spectra were determined with a Bruker microTOF spectrometer using electrospray ionization (ESI source). For mass spectra, solutions were made in HPLC grade methanol.
Flash column chromatography was performed with silica gel 60 (230-400mesh) (Merck) and TLC was carried out on precoated silica plates (kiesel gel 60 F254, BDH). Compounds were visualised by illumination under UV light (254 nm). Melting points were determined on an electrothermal instrument and are uncorrected. All solvents were dried prior to use and stored over 4 Å molecular sieves, under nitrogen. All final compounds were more than 95% pure.
Intermediates 5-8 were generally prepared according to literature procedures, which are described in detail along with compound characterisation in the Supporting Information. Details for the preparation and full characterisation of the new target compounds 9-40 are given below.
General method for the preparation of (thieno[2,3-d]pyrimidin-4-yl)-hydrazones 1, 9-26
The different (thieno[2,3-d]pyrimidin-4-yl)-hydrazine (8a-d or f-i) (1 eq.) and arylketone or aldheyde (1.2) were dissolved in EtOH (12 mL/mmol eq.), and the mixture was refluxed for 24 h. The reaction mixture was then cooled to r.t and placed in a fridge o.n. The resulting precipitate was filtered, washed with a cold solution of 80% EtOH in water and crystallised from EtOH unless otherwise stated.
Most hydrazone products show two sets of signals in NMR experiments. All 1 H-NMR spectra of the new hydrazone compounds are reported for clarity in the Supporting Information.
Obtained in 66% yield as a yellow solid. M.p. >300 °C. 
General method for the preparation of (thieno[2,3-d]pyrimidin-4-yl)-hydrazides 25-36
The aryl carboxylic acid (1.1 eq.) and TBTU (1.2) were suspended in anhydrous THF (11 mL/mmol eq.) at r.t. under N2 atmosphere. DiPEA (2.4 eq.) was then added dropwise to the reaction mixture, followed by the different (thieno[2,3-d]pyrimidin-4-yl)-hydrazine (8a-d or f-i) (1 eq.) dissolved in anhydrous THF (11 mL/mmol eq.). The mixture was stirred at r.t. for 4 h, then concentrated under vacuum. The residue was dissolved in EtOAc (30 mL/mmol eq.), washed with water (30 mL/mmol eq.), saturated NaHCO3 solution (30 mL/mmol eq.), and finally with brine (30 mL/mmol eq.). The organic phase was concentrated under vacuum after drying over MgSO4. The crude residue was purified by recrystallisation or flash column chromatography. 
2-Hydroxy-benzoic acid N'-(5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidin-4-yl)-
hydrazide (26a) [45] Purified by crystallisation from EtOH/H2O. Obtained in 35% yield as a light orange solid. M.p. 327-329 °C. carried out using GlideSP module in Maestro [29] with the default options. A 12 Å docking grid was generated using as centroid defined by Arg393, Glu493 and Trp501 in the 3KQH crystal structure.
Docking results were rescored using Plants ChemPLP [31] , FlexX [32] and Glide XP [30] scoring functions.
HCV replicon assay
The compounds were dissolved in dimethyl sulfoxide, stored at -20 °C protected from light and further Four-step, 1-to-5 compound dilution series were prepared for the first screen, to collect data for a more detailed dose-response curve, an eight-step, 1-to-2 dilution series was used. Following assay setup, the microtiter plates were incubated for 72 hours (37 °C, 5% CO2, 95-99% relative humidity). For the evaluation of anti-metabolic effects, the assay medium was aspirated, replaced with 75 μL of a 5% MTS solution in phenol red-free medium and incubated for 1.5 hours (37 °C, 5% CO2, 95-99% relative humidity). Absorbance was measured at a wavelength of 498 nm (Safire2, Tecan), and optical densities (OD values) were converted to percentage of untreated controls. For the evaluation of antiviral effects, assay medium was aspirated and the cell monolayers were washed with PBS. The wash buffer was aspirated, and 25 μL of Glo Lysis Buffer (Promega) was added allowing for cell lysis to proceed for 5 min at room temperature. Subsequently, 50 μL of Luciferase Assay System (Promega) was added, and the luciferase luminescence signal was quantified immediately (1000 ms integration time/well, Safire, Tecan). Relative luminescence units were converted into percentage of untreated controls.
The EC50 and EC90 (values calculated from the dose-response curve) represent the concentrations at which 50% and 90% inhibition, respectively, of viral replication is achieved. The CC50 (value calculated from the dose-response curve) represents the concentration at which the metabolic activity of the cells is reduced by 50% as compared to untreated cells.
HCV NS3 helicase enzymatic assays
Molecular beacon-based NS3 helicase assays were performed as described by Hanson et al. [47] Reactions contained 25mM MOPS pH 6.5, 1.25mM MgCl2, 5% DMSO, 5 µg/ml BSA, 0.01% (v/v) Tween20, 0.05 mM DTT, 5 nM florescent DNA substrate, 12.5 nM NS3h, and 1 mM ATP. The ability of each compound to displace NS3 from a DNA oligonucleotide was monitored as described by
Mukherjee et al. [48] . Each assay contained 15 nM NS3h, 25 mM MOPS, pH 7.5, 1.25 mM MgCl2, 0.0025 mg/ml BSA, 0.005% (v/v) Tween20, 0.025 mM DTT and 12.5nM NS3h_(1b). The ability of NS3
to hydrolyze ATP was monitored as described by Sweeney et al. [49] . Reactions performed in the presence of RNA contained 25mM MOPS pH 6.5, 1.25mM MgCl2, 15 µM Poly U RNA (Sigma), 6 nM NS3h_1b(con1) in 5 μg/mL BSA, 0.001% Tween 20. Reactions performed in the absence of RNA contained all the same reagents except that 300 nM NS3h _1b(con1) was included. To determine the compound concentration needed to reduce helicase catalyzed ATP hydrolysis by 50 % (IC50), reactions were performed in duplicate two-fold dilution series such that final compound concentrations ranged from 0.5 mM to 0.78 µM. Data obtained from all reactions within the linear range of the assays were normalized to controls lacking inhibitor (100%) and controls lacking enzyme (0%), and fit to a normalized dose response equation with a variable Hill slope using GraphPad Prism (v. 6). Reactions were performed in duplicate and each titration was fit to the above concentration response equation.
Average IC50 values ± standard deviations are reported.
